A series of fluorescent dibenzodiazepinone-type muscarinic acetylcholine M receptor (MR) ligands was synthesized using various fluorescent dyes (5-TAMRA, / ≈ 547/576 nm; BODIPY 630/650, / ≈ 625/640 nm; pyridinium dye Py-1, / ≈ 611/665 nm and pyridinium dye Py-5, / ≈ 465/732 nm). All fluorescent probes exhibited high MR affinity (p (radioligand competition binding): 8.75-9.62, p (flow cytometry): 8.36-9.19), a very low preference for the MR over the M and M receptors and moderate to pronounced MR selectivity compared to the M and M receptors. The presented fluorescent ligands are considered useful molecular tools for future studies using methods such as fluorescence anisotropy and BRET based MR binding assays.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650007 | PMC |
http://dx.doi.org/10.1039/d0md00137f | DOI Listing |
Bioconjug Chem
November 2022
School of Biological and Health Systems Engineering, Arizona State University, Tempe, Arizona85281, United States.
The development of fluorescently labeled receptor-targeting compounds represents a powerful pharmacological tool to study and characterize ligand-receptor interactions. Despite significant advances in developing sub-type-specific antagonists for muscarinic acetylcholine receptors (mAChRs), reports on antagonists feasible for click chemistry are less common. Here, we designed and synthesized an antagonist suitable for probe attachment through click chemistry, namely, dibenzodiazepinone (DIBA)-alkyne, based on a previously reported DIBA scaffold with a high binding affinity to type-2 mAChR (MR).
View Article and Find Full Text PDFEur J Med Chem
March 2021
Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstraße 31, D-93053, Regensburg, Germany. Electronic address:
The family of human muscarinic acetylcholine receptors (MRs) is characterized by a high sequence homology among the five subtypes (MR-MR), being the reason for a lack of subtype selective MR ligands. In continuation of our work on dualsteric dibenzodiazepinone-type MR antagonists, a series of MR ligands containing a dibenzodiazepinone pharmacophore linked to small basic peptides was synthesized (64 compounds). The linker moiety was varied with respect to length, number of basic nitrogens (0-2) and flexibility.
View Article and Find Full Text PDFRSC Med Chem
July 2020
Institute of Pharmacy , Faculty of Chemistry and Pharmacy , University of Regensburg , Universitätsstrasse 31, D-93053 Regensburg , Germany . Email:
A series of fluorescent dibenzodiazepinone-type muscarinic acetylcholine M receptor (MR) ligands was synthesized using various fluorescent dyes (5-TAMRA, / ≈ 547/576 nm; BODIPY 630/650, / ≈ 625/640 nm; pyridinium dye Py-1, / ≈ 611/665 nm and pyridinium dye Py-5, / ≈ 465/732 nm). All fluorescent probes exhibited high MR affinity (p (radioligand competition binding): 8.75-9.
View Article and Find Full Text PDFJ Med Chem
April 2020
Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstr. 31, D-93053 Regensburg, Germany.
Fluorescently labeled dibenzodiazepinone-type muscarinic acetylcholine receptor (MR) antagonists, including dimeric ligands, were prepared using red-emitting cyanine dyes. Probes containing a fluorophore with negative charge showed high MR affinities (p (radioligand competition binding): 9.10-9.
View Article and Find Full Text PDFJ Med Chem
June 2019
Institute of Pharmacy, Faculty of Chemistry and Pharmacy , University of Regensburg , Universitätsstraße 31, D-93053 Regensburg , Germany.
Muscarinic acetylcholine receptors (MRs), comprising five subtypes (MR-MR) in humans, exhibit a high degree of structural similarity. Therefore, subtype-selective MR agonists and antagonists are lacking. We present an approach to highly MR-selective MR antagonists based on the conjugation of di- or tripeptides to MR-preferring dibenzodiazepinone-type MR antagonists.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!